silodosin
Rapaflo	Pharmaceutical company: Watson Pharmaceuticals, Inc. www.rapaflo.com

Pharmacologic classification: alpha-1 adrenergic receptor antagonist
Therapeutic classification: benign prostatic hyperplasia (BPH) drug
Pregnancy risk category: B

AVAILABLE FORMS
Capsules: 4 mg, 8 mg

INDICATIONS AND DOSAGES
To improve symptoms of BPH—
Men: 8 mg P.O. once daily.
ADJUST-A-DOSE: For patients with a creatinine clearance of 30 to 50 ml/minute, 4 mg once daily.

CONTRAINDICATIONS AND CAUTIONS
Contraindicated in patients with severe renal or hepatic impairment and in those taking strong CYP3A4 inhibitors.

INTERACTIONS
Drug-drug. Strong CYP3A4 inhibitors (ketoconazole, clarithromycin, itraconazole, ritonavir): May increase silodosin level. Avoid use together.
Moderate CYP3A4 inhibitors (diltiazem, erythromycin, verapamil): May increase silodosin level. Use together cautiously.
Alpha blockers: May cause interactions. Avoid use together.
Strong P-glycoprotein inhibitors (cyclosporine): May increase silodosin levels. Don't use together.
Antihypertensives: May cause dizziness and orthostatic hypotension. Use together cautiously and monitor patient for adverse reactions.
Drug-food. Moderate fat and calorie intake: May decrease silodosin concentration. Administer with food to minimize adverse reactions.

ADVERSE REACTIONS
CNS: asthenia, dizziness, headache, insomnia.
CV: orthostatic hypotension.
EENT: nasal congestion, nasopharyngitis, rhinorrhea, sinusitis.
GI: abdominal pain, diarrhea.
GU: retrograde ejaculation.

Reactions may be common, uncommon, life-threatening, or COMMON AND LIFE-THREATENING.

Home - Guest Registry - Customer Service

Brought to you by Lippincott Williams & Wilkins,
publisher of Lippincott's Nursing Drug Guide.
For help on how you should use this site, see our Disclaimer.

© Copyright 2010 by Lippincott Williams & Wilkins